Journal Article

Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high‐dose folic acid supplementation

Katsushi Koyama, Takeshi Usami, Oki Takeuchi, Kunio Morozumi and Genjiro Kimura

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue 5, pages 916-922
Published in print May 2002 | ISSN: 0931-0509
Published online May 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.5.916
Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high‐dose folic acid supplementation

Show Summary Details

Preview

Background. Hyperhomocysteinaemia, which is considered to be induced by impairment of the remethylation pathway in patients with chronic renal failure (CRF), cannot be cured solely by folic acid therapy. In the present study, we investigated the additional benefit of administration of methylcobalamin, which is a co‐enzyme in the remethylation pathway, on lowering total homocysteine (tHcy) plasma concentrations in haemodialysis (HD) patients receiving high‐dose folic acid supplementation.

Methods. In order to assess the efficacy on lowering plasma tHcy levels (fasting concentration), 21 HD patients, were randomly assigned and provided folic acid supplementation: 15 mg/day orally (group I, n=7); methylcobalamin 500 mg intravenously after each HD, in addition to folic acid (group II, n=7); or vitamin B6 (B6), 60 mg/day orally, in addition to folic acid and methylcobalamin (group III, n=7). All patients were treated for 3 weeks. A methionine‐loading test was conducted before and after supplementation. The following measurements were also made before and after supplementation for each group: serum folic acid, B6, and vitamin B12 (B12) concentrations (including measurement of proportion of methylcobalamin fraction). Twelve HD patients receiving methylcobalamin alone served as the HD control group and seven healthy volunteers served as the normal control group for this study.

Results. In our randomized HD patients the proportions of methylcobalamin fraction (48.3±7.5%) and plasma vitamin B6 concentration (2.9±1.1 ng/ml) were significantly lower than in the normal controls (methylcobalamin 58.7±2.2%, P<0.01; B6 20.1±10.8 ng/ml, P<0.01), while folic acid and vitamin B12 were not significantly different from the normal controls. Mean percentage reduction in fasting tHcy was 17.3±8.4% in group I, 57.4±13.3% in group II, 59.9±5.6% in group III, and 18.7±7.5% in HD controls. The power of the test to detect a reduction of tHcy level was 99.6% in group II and 99.9% in group III when type I error level was set at 0.05. Groups II and III had normal results for the methionine‐loading test after treatment. Treatment resulted in normalization of fasting tHcy levels (<12 ng/ml) in all 14 patients treated by the combined administration of methylcobalamin and supplementation of folic acid regardless of whether there was supplementation of vitamin B6.

Conclusion. The benefit of methylcobalamin administration on lowering plasma tHcy levels in HD patients was remarkable. Our study suggested that both supplementations of high‐dose folic acid and methylcobalamin are required for the remethylation pathway to regain its normal activity. This method could be a therapeutic strategy to combat the risk associated with atherosclerosis and cardiovascular disease in patients with chronic renal failure.

Keywords: chronic renal failure; folic acid; haemodialysis; homocysteine; methylcobalamin; vitamin B12

Journal Article.  4307 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.